OncLive - Binod Dhakal, MD, discusses the potential impact of ide-cel, orva-cel, and cilta-cel in multiple myeloma...
Twitter Feed: OncLive SOSS
Assessing the Advantages of Adjuvant Targeted Therapy in Lung Cancer
posted 12 hours
Mashup Score: 1
OncLive - David Spigel, MD, discusses the future of adjuvant targeted therapy in lung...
-
.@dave6408, of @SarahCannonDocs, discusses the future of adjuvant targeted therapy in lung cancer #lcsm https://t.co/PhjcHZ0eow https://t.co/PhjcHZ0eow
OncLive - Cindy B. Matsen, MD, discusses the potential effects of the decrease in screening for patients with breast cancer during the coronavirus disease 2019...
-
.@cbmatsen, of @huntsmancancer, discusses the potential effects of the decrease in screening for patients with breast cancer during the coronavirus disease 2019 pandemic #bcsm https://t.co/LpEwMU3XKY https://t.co/LpEwMU3XKY
OncLive - Natalie S. Callander, MD, discusses selecting a frontline treatment strategy for patients with multiple...
-
.@nsc_natalie, of @UWCarbone, discusses selecting a frontline treatment strategy for patients with multiple myeloma #mmsm https://t.co/bp7BwbYHZn https://t.co/bp7BwbYHZn
OncLive - The FDA has issued a complete response letter to Athenex, Inc. stating that it will not, at this time, approve the new drug application...
-
#ICYMI: @US_FDA has issued a complete response letter to Athenex, Inc. stating that it will not, at this time, approve the new drug application for oral paclitaxel in combination with encequidar for the treatment of patients with metastatic breast cancer https://t.co/2WDygY2D6e
OncLive - Claud N. Grigg, MD, highlights different frontline combination regimens that are improving outcomes for patients with metastatic renal cell...
-
Claud N. Grigg, MD, of @LevineCancer, highlights different frontline combination regimens that are improving outcomes for patients with metastatic renal cell carcinoma #kcsm https://t.co/LiErtLzHRv https://t.co/LiErtLzHRv
OncLive - Timothy M. Schmidt, MD, discusses the utilization of bispecific antibodies in...
-
.@TMSchmidtMD, of @UWCarbone, discusses the utilization of bispecific antibodies in myeloma #mmsm https://t.co/1Uamfk8Ngg https://t.co/1Uamfk8Ngg
OncLive - Davey B. Daniel, MD, discusses key immunotherapy trials in advanced non–small cell lung cancer and explains how the results can be extrapolated to clinical...
-
Davey B. Daniel, MD, of @TNOncology, discusses key immunotherapy trials in advanced non–small cell lung cancer and explains how the results can be extrapolated to clinical practice #lcsm https://t.co/QDJtAaf0n0 https://t.co/QDJtAaf0n0
OncLive - Tanios S. Bekaii-Saab, MD, FACP, discusses indicators of progression in colorectal...
-
.@GIcancerDoc, of @MayoClinic, discusses indicators of progression in colorectal cancer #stomca https://t.co/zz5YuRMTbX https://t.co/zz5YuRMTbX
OncLive - Yi Lin, MD, PhD, discusses the importance of developing non-BCMA–targeting agents in multiple...
-
.@YiLinMDPhD, of @MayoClinic, discusses the importance of developing non-BCMA–targeting agents in multiple myeloma #mmsm https://t.co/jXrpocNGz8 https://t.co/jXrpocNGz8
.@bhemato, of @MedicalCollege, discusses the potential impact of ide-cel, orva-cel, and cilta-cel in multiple myeloma therapy #mmsm https://t.co/4DWYH9bJ9g https://t.co/4DWYH9bJ9g